Effect of proton pump inhibitors versus histamine-2 receptor antagonists on acute kidney injury in septic patients at high risk for developing stress ulcers

被引:0
|
作者
Fan, Hua-Ping [1 ]
Zhou, Yu [1 ]
Chen, Mei-Li [2 ]
Qiu, Kun-Hua [3 ]
Feng, Xue [1 ]
Zhou, Chao [1 ]
Zhu, Min-Li [4 ]
Huang, Rong-Zhong [5 ]
Hu, Tian-Yang [5 ]
机构
[1] 63650 Mil Hosp, Dept Cardiol, Xinjiang, Peoples R China
[2] 63650 Mil Hosp, Dept Respirol & Gastroenterol, Xinjiang, Peoples R China
[3] 63650 Mil Hosp, Dept Prevent Med, Xinjiang, Peoples R China
[4] Special Med Ctr Strateg Support Force, Dept Resp Med, Beijing, Peoples R China
[5] Chongqing Med Univ, Affiliated Hosp 2, Precis Med Ctr, 74 Linjiang Rd, Chongqing 400010, Peoples R China
来源
PHARMACOTHERAPY | 2024年 / 44卷 / 07期
关键词
acute kidney injury; histamine-2 receptor antagonists; proton pump inhibitors; sepsis; stress ulcer prophylaxis; INTERNATIONAL CONSENSUS DEFINITIONS; CRITICALLY-ILL PATIENTS; CLINICAL CHARACTERISTICS; SEPSIS; FAILURE;
D O I
10.1002/phar.2947
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundTo compare the effects of proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) use on the occurrence of acute kidney injury (AKI) in septic patients at high risk for developing stress ulcers.MethodsUsing the Medical Information Mart for Intensive Care IV version 2.2 database, septic patients with high-risk factors for stress ulcers (i.e., shock, coagulopathy, invasive mechanical ventilation, or chronic liver diseases) were included. Exposures included PPIs and H2RAs within 24 h of intensive care unit (ICU) admission or prior to ICU admission. The primary end point was severe sepsis-associated AKI as defined by the Kidney Disease Improving Global Outcomes criteria stage 3 (KDIGO-3). Propensity score matching (PSM) was performed to balance baseline characteristics. Multivariable Cox proportional hazards regression was used to estimate the effect size.Results4731 PPI users and 4903 H2RA users were included. After PSM, there were 1785 pairs exposed to PPIs and H2RAs. In the PSM cohort, the cumulative incident KDIGO-3 rate was higher in the PPI group than in the H2RA group (log-rank test, p = 0.009). Regression analyses showed that PPI exposure [adjusted hazard ratio 1.32, 95% confidence interval (CI) 1.11-1.58, p = 0.002] was associated with incident KDIGO-3 compared with H2RA use. This association remained consistent in sensitivity analyses. Additionally, the PPI group had a higher need for kidney replacement therapy compared with the H2RA group (3.6% vs. 2.1%, P = 0.012).ConclusionsAmong septic patients at high risk for developing stress ulcers, PPI exposure was associated with incident KDIGO-3 AKI compared with H2RA use.
引用
收藏
页码:539 / 548
页数:10
相关论文
共 50 条
  • [21] Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies
    Liu, Peipei
    McMenamin, Una
    Johnston, Brian
    Murchie, Peter
    Iversen, Lisa
    Lee, Amanda
    Vissers, Pauline
    Cardwell, Christopher
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 45 - 45
  • [22] Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis
    Azab, Mohamed
    Doo, Loomee
    Doo, Daniel H.
    Elmofti, Yousif
    Ahmed, Muazer
    Cadavona, John Jay
    Liu, Xibei B.
    Shafi, Amaan
    Joo, Moon Kyung
    Yoo, Ji Won
    GUT AND LIVER, 2017, 11 (06) : 781 - 788
  • [23] Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies
    Peipei Liu
    Úna C. McMenamin
    Brian T. Johnston
    Peter Murchie
    Lisa Iversen
    Amanda J. Lee
    Pauline A. J. Vissers
    Chris R. Cardwell
    British Journal of Cancer, 2020, 123 : 307 - 315
  • [24] Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies
    Liu, Peipei
    McMenamin, Una C.
    Johnston, Brian T.
    Murchie, Peter
    Iversen, Lisa
    Lee, Amanda J.
    Vissers, Pauline A. J.
    Cardwell, Chris R.
    BRITISH JOURNAL OF CANCER, 2020, 123 (02) : 307 - 315
  • [25] Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events
    MacLaren, Robert
    Kassel, Lynn E.
    Kiser, Tyree H.
    Fish, Douglas N.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (02) : 269 - 280
  • [26] Proton pump inhibitors versus histamine-2 receptor antagonists for stress ulcer prophylaxis during extracorporeal membrane oxygenation: a propensity score-matched analysis
    Kondo, Yutaka
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanaka, Hiroshi
    Yasunaga, Hideo
    BMJ OPEN, 2020, 10 (09): : e037534
  • [27] Proton Pump Inhibitors Versus Histamine-2 Receptor Antagonists Likely Increase Mortality in Critical Care: An Updated Meta-Analysis
    Lee, Todd C.
    Wilson, Marnie Goodwin
    Lawandi, Alexander
    McDonald, Emily G.
    AMERICAN JOURNAL OF MEDICINE, 2021, 134 (03): : E184 - E188
  • [28] Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists
    Houben, Eline
    Johansson, Saga
    Nagy, Peter
    Penning-van Beest, Fernie J. A.
    Kuipers, Ernst J.
    Herings, Ron M. C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (04) : 577 - 583
  • [29] Histamine-2 receptor antagonists at night improve GERD symptoms for patients on proton pump inhibitor therapy
    Rackoff, A
    Agrawal, A
    Hila, A
    Mainie, I
    Tutuian, R
    Freeman, J
    Castell, DO
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S18 - S18
  • [30] Delirium risk of histamine-2 receptor antagonists and proton pump inhibitors: A study based on the adverse drug event reporting database in Japan
    Kikkawa, Nao
    Sogawa, Rintaro
    Monji, Akira
    Sumi, Shintaro
    Murakawa-Hirachi, Toru
    Kubo, Toshiki
    Eguchi, Yuko
    Miyamoto, Yuki
    Kamo, Masahiro
    Tobita, Shuko
    Yukawa, Misako
    Uchida, Rina
    Egoshi, Masayoshi
    Shimanoe, Chisato
    GENERAL HOSPITAL PSYCHIATRY, 2021, 72 : 88 - 91